Use of different diagnostic methods for ventilator-associated pneumonia did not affect mortality or targeted antibiotic usePDF
ACP J Club. 2007 May-Jun;146:62. doi:10.7326/ACPJC-2007-146-3-062
Clinical Impact Ratings
Heyland D, Cook D, Dodek P, Muscedere J, Day A. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med. 2006;355:2619-30. [PubMed ID: 17182987]
In critically ill patients suspected of having ventilator-associated pneumonia (VAP), does the diagnostic method used affect mortality and antibiotic use?
Design: Randomized controlled trial.
Follow-up period: 28 days or to hospital discharge.
Setting: 28 intensive care units (ICUs) in Canada and the United States.
Patients: 740 critically ill patients ≥ 18 years of age (mean age 59 y, 69% men) who had received mechanical ventilation in the ICU for ≥ 4 days and were suspected of having VAP. Patients were excluded if they were immunocompromised, unsuitable for bronchoscopy, or infected or colonized with Pseudomonas species or methicillin-resistant Staphylococcus aureus.
Intervention: Bronchoalveolar lavage (BAL) with quantitative culture of the bronchoalveolar-lavage fluid (n = 365) or endotracheal aspiration (ETA) with nonquantitative culture of the aspirate (n = 375). Empirical intravenous antibiotic therapy (meropenem, 1 g every 8 h, with or without ciprofloxacin, 400 mg every 12 h, randomly assigned) was initiated in all patients until culture results were available, at which time a protocol of targeted therapy was to be used.
Outcomes: 28-day mortality, ICU and hospital mortality and length of stay, duration of mechanical ventilation, and use of targeted therapy after culture results were known.
Patient follow-up: 99.9% (intention-to-treat analysis).
A positive culture was identified in 60% of patients in the BAL group and 52% in the ETA group (P = 0.03). Groups did not differ for 28-day, ICU, or hospital mortality; use of targeted therapy by day 6 (Table); or rates of clinical and microbial cure at 28 days. The BAL and ETA groups had similar median durations (after randomization) of mechanical ventilation (8.9 vs 8.8 d, P = 0.31), ICU stay (12 vs 12 d, P = 0.22), and hospital stay (40 vs 47 d, P = 0.13).
In critically ill patients suspected of having ventilator-associated pneumonia, a diagnostic strategy using bronchoalveolar lavage with quantitative culture was associated with mortality and overall antibiotic use similar to that of a strategy based on endotracheal aspiration with nonquantitative culture.
Sources of funding: Canadian Institutes of Health Research; Physicians' Services Incorporated of Ontario; AstraZeneca; Bayer.
For correspondence: Dr. D. Heyland, Kingston General Hospital, Kingston, Ontario, Canada. E-mail firstname.lastname@example.org.
Table. Bronchoalveolar lavage vs endotracheal aspiration for diagnosis of ventilator-associated pneumonia in critically ill patients†
|Outcomes||Bronchoalveolar lavage||Endotracheal aspiration||RRI (95% CI)||NNH|
|28-day mortality||19%||18%||1% (−25 to 37)‡||Not significant|
|Intensive care unit mortality||16%||17%||10% (−25 to 35)‡||Not significant|
|Hospital mortality||23%||26%||13% (−12 to 33)‡||Not significant|
|Targeted therapy at 6 d||74%||75%||0% (−8 to 9)||Not significant|
†RBR = relative benefit reduction. Other abbreviations defined in Glossary; RRI, RRR, RBR, NNH, NNT, and CI calculated from data in article.
‡Adjusted for Acute Physiology and Chronic Health Evaluation (APACHE) II score and type of empirical antibiotic regimen.
The study by the Canadian Critical Care Trials Group (CCCTG) is the largest to date to compare “invasive” (i.e., bronchoscopic BAL and quantitative cultures) and “noninvasive” (i.e., ETA and nonquantitative cultures) sampling techniques to diagnose VAP. The study found no evidence of superiority of the invasive approach, contrary to the results of the second largest study done in France (1).
The CCCTG trial used a factorial design to evaluate both the diagnostic approach and antibiotic therapy (single vs combination), assuming that the 2 interventions would not interact. However, using a fixed empirical regimen is problematic because acting on early culture results is an integral part of the “invasive” strategy, which was used in the French study. Indeed, the 2 studies differed in several important respects. In the CCCTG trial, BAL fluid culture was considered positive if a potential pathogen was isolated, regardless of the colony count, which probably explains both the unexpected finding of a higher rate of positive BAL fluid cultures and the very high proportion of patients (85%) classified as having pneumonia. Furthermore, Gram stains were used in part to initiate therapy and early cultures were used to adapt therapy in both groups of the French trial, whereas all patients in the CCCTG trial received broad-spectrum therapy for a median of 3 days. Finally, the CCCTG trial excluded patients known to be colonized with “high-risk” organisms; however, it is in this more difficult-to-treat population that the invasive–quantitative techniques may be most useful.
While ample evidence exists that early appropriate treatment of patients with sepsis is important, broad-spectrum antibiotic coverage for all patients clinically suspected of pneumonia is questionable. As many as half such patients may not have overt sepsis or even pneumonia. When all patients with suspected VAP receive broad-spectrum antibiotic coverage for several days, the outcome is mainly driven by the adequacy of the empirical regimen and is unlikely to be affected by culture results. Although the CCCTG study adds to our knowledge, it does not provide a definitive answer to the respective value of alternative strategies for diagnosing VAP.
Christian Brun-Buisson, MD, PhD
Hôpital Henri Mondor and Université Paris XII